乳がんリキッドバイオプシー市場規模、シェア、成長分析、循環バイオマーカー別、用途別、地域別 - 産業予測、2024～2031年

乳がんリキッドバイオプシーの世界市場規模は、2022年に10億1,000万米ドルと評価され、2023年の12億4,000万米ドルから2031年には63億7,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは22.7％で成長する見通しです。

世界の乳がんリキッドバイオプシー市場は、認知度の向上と非侵襲的診断法の採用が拍車をかけ、大幅な成長を遂げています。この革新的な技術は、早期診断、治療法の選択、治療に対する反応のモニタリングに不可欠な腫瘍特異的遺伝子変異、循環腫瘍細胞、無細胞DNAの検出を容易にします。現在進行中の研究開発によってリキッドバイオプシー検査の感度と特異性が向上するにつれて、市場の拡大が予想されます。バイオテクノロジー企業とヘルスケア機関の協力体制は、個別化された標的乳がん治療に対する需要の高まりと相まって、市場の拡大をさらに後押ししています。全体として、技術革新と臨床応用の融合により、リキッドバイオプシー市場は今後数年間で顕著な成長を遂げるものと思われます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2023年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術の進歩
• ケーススタディ分析

乳がんリキッドバイオプシー市場規模：循環バイオマーカー別およびCAGR（2024～2031年）

• 市場概要
• 循環腫瘍細胞（CTCS）
• 循環遊離DNA（CFDNA）
• 細胞外小胞（EVS）
• その他の循環バイオマーカー

乳がんリキッドバイオプシー市場規模：用途別およびCAGR（2024～2031年）

• 市場概要
• 早期発見・スクリーニング
• 診断
• 治療の選択
• 監視

乳がんリキッドバイオプシー市場規模：エンドユーザー別およびCAGR（2024～2031年）

• 市場概要
• 病院
• クリニック
• その他

乳がんリキッドバイオプシー市場規模およびCAGR（2024～2031年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2023年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2021～2023年）

主要企業プロファイル

• F. Hoffmann-La Roche Ltd
• Bio-Rad Laboratories Inc.
• Illumina Inc.
• Guardant Health Inc.
• QIAGEN
• Biocept Inc.
• Thermo Fisher Scientific
• Adaptive Biotechnologies
• Myriad Genetics
• Fluxion Biosciences Inc.
• Biodesix
• Exosome Diagnostics Inc.
• Epic Sciences
• PapGene
• Pathway Genomics（OME Care）
• Agena Bioscience
• MDxHealth
• Janssen Diagnostics
• Abbott

結論と推奨事項

Global Breast Cancer Liquid Biopsy Market size was valued at USD 1.01 billion in 2022 and is poised to grow from USD 1.24 billion in 2023 to USD 6.37 billion by 2031, growing at a CAGR of 22.7% during the forecast period (2024-2031).

The global breast cancer liquid biopsy market is witnessing substantial growth, spurred by rising awareness and the adoption of non-invasive diagnostic methods. This innovative technology facilitates the detection of tumor-specific genetic mutations, circulating tumor cells, and cell-free DNA, critical for early diagnosis, treatment selection, and monitoring responses to therapies. As ongoing research and development improve the sensitivity and specificity of liquid biopsy tests, market expansion is anticipated. Collaborative efforts between biotech firms and healthcare institutions, coupled with increasing demand for personalized and targeted breast cancer therapies, are further propelling the market's progression. Overall, the convergence of innovation and clinical application positions the liquid biopsy market for notable growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Breast Cancer Liquid Biopsy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Breast Cancer Liquid Biopsy Market Segmental Analysis

Global Breast Cancer Liquid Biopsy Market is segmented by circulating biomarkers, application, end users and region. Based on circulating biomarkers, the market is segmented into circulating tumor cells (CTCS), circulating cell-free DNA (CFDNA), extracellular vesicles (EVS) and other circulating biomarkers. Based on application, the market is segmented into early detection/screening, diagnosis, treatment selection and monitoring. Based on end users, the market is segmented into hospitals, clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Breast Cancer Liquid Biopsy Market

The global breast cancer liquid biopsy market is primarily propelled by the growing demand to effectively tackle breast cancer. The rising use of liquid biopsy methods serves as a key motivator, as these techniques facilitate the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and various biomarkers found in blood samples. This innovation enables healthcare providers to make better-informed treatment choices. Furthermore, liquid biopsies can detect resistance mutations and minimal residual disease, enhancing personalized treatment approaches. As a result, this technology not only improves patient outcomes but also contributes to lowering overall healthcare expenses.

Restraints in the Global Breast Cancer Liquid Biopsy Market

The global breast cancer liquid biopsy market faces several significant restraints, primarily stemming from inadequate investment in healthcare infrastructure. While liquid biopsy tests show considerable promise, their high costs present a substantial barrier to accessibility, particularly for patients with limited financial means or those in areas with poor healthcare funding. The considerable investment required for the development and deployment of advanced liquid biopsy technologies often leads to elevated testing costs, making them less feasible for many individuals. Furthermore, challenges related to reimbursement policies and regulatory approvals hamper widespread adoption, highlighting the critical need to address these financial barriers to enhance equitable access to these crucial diagnostic tools for breast cancer patients worldwide.

Market Trends of the Global Breast Cancer Liquid Biopsy Market

The Global Breast Cancer Liquid Biopsy market is witnessing a significant upward trend, driven by the increasing demand for non-invasive diagnostic methods aimed at early detection and monitoring of breast cancer. As healthcare professionals and patients alike seek alternatives to traditional tissue biopsies, liquid biopsies are gaining traction for their ability to provide timely and accurate genomic insights with minimal discomfort. Technological advancements in assay development and an escalating focus on personalized medicine are further propelling this market. Additionally, rising awareness and supportive regulatory frameworks are fostering a conducive environment for innovation, ultimately driving growth in the breast cancer liquid biopsy sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Case Study Analysis

Global Breast Cancer Liquid Biopsy Market Size by Circulating Biomarkers & CAGR (2024-2031)

• Market Overview
• Circulating Tumor Cells (CTCS)
• Circulating Cell-Free DNA (CFDNA)
• Extracellular Vesicles (EVS)
• Other Circulating Biomarkers

Global Breast Cancer Liquid Biopsy Market Size by Application & CAGR (2024-2031)

• Market Overview
• Early Detection/Screening
• Diagnosis
• Treatment Selection
• Monitoring

Global Breast Cancer Liquid Biopsy Market Size by End Users & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics
• Others

Global Breast Cancer Liquid Biopsy Market Size & CAGR (2024-2031)

• North America (Circulating Biomarkers, Application, End Users)
  • USA
  • Canada
• Europe (Circulating Biomarkers, Application, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Circulating Biomarkers, Application, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Circulating Biomarkers, Application, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Circulating Biomarkers, Application, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocept Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptive Biotechnologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fluxion Biosciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biodesix
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exosome Diagnostics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epic Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PapGene
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pathway Genomics (OME Care)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agena Bioscience
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MDxHealth
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations